Literature DB >> 10591554

Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization.

T Tajiri1, K Shono, Y Fujii, S Noguchi, Y Kinoshita, M Tsuneyoshi, S Suita.   

Abstract

BACKGROUND/
PURPOSE: The N-myc amplification status in neuroblastoma has been evaluated previously for the whole tumor by the Southern blot method. The aim of this study is to evaluate the effectiveness of the fluorescence in situ hybridization (FISH) method to analyze N-myc amplification in neuroblastoma and compare the findings with those using the Southern blot method.
METHODS: In 26 neuroblastoma primary tumors and metastatic lesions, the N-myc amplification status was evaluated by both the Southern blot method and FISH method.
RESULTS: Of the 22 samples with no N-myc amplification using Southern blot, no cells with N-myc amplification using FISH were present in 21 of the samples. However, one metastatic liver lesion showed 16% of the nuclei to display more than 10 copies of N-myc based on FISH analysis. In the 4 remaining samples with N-myc amplification using the Southern blot method (17 copies, 15 copies, 6 copies, and 3 copies), the rates of cells with more than 10 copies of N-myc based on a FISH analysis were 79%, 68%, 94%, and 9%, respectively.
CONCLUSIONS: The FISH method can detect more accurately N-myc amplification than the Southern blot method either when the rate of cells with N-myc amplification is low or intratumor heterogeneity is present.

Entities:  

Mesh:

Year:  1999        PMID: 10591554     DOI: 10.1016/s0022-3468(99)90628-0

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.

Authors:  Ryota Souzaki; Tatsuro Tajiri; Risa Teshiba; Mayumi Higashi; Yoshiaki Kinoshita; Sakura Tanaka; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2011-03       Impact factor: 1.827

2.  Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.

Authors:  Ryota Souzaki; Tatsuro Tajiri; Mayumi Higashi; Yoshiaki Kinoshita; Sakura Tanaka; Kenichi Kohashi; Masazumi Tsuneyoshi; Tomoaki Taguchi
Journal:  Pediatr Surg Int       Date:  2008-10       Impact factor: 1.827

3.  B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma.

Authors:  Wen-Ming Hsu; Mei-Ieng Che; Yung-Feng Liao; Hsiu-Hao Chang; Chia-Hua Chen; Yu-Ming Huang; Yung-Ming Jeng; John Huang; Michael J Quon; Hsinyu Lee; Hsiu-Chin Huang; Min-Chuan Huang
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

4.  Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma.

Authors:  Pei-Yi Wu; Yung-Feng Liao; Hsueh-Fen Juan; Hsuan-Cheng Huang; Bo-Jeng Wang; Yen-Lin Lu; I-Shing Yu; Yu-Yin Shih; Yung-Ming Jeng; Wen-Ming Hsu; Hsinyu Lee
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.